In conclusion, our results indicate that, except for irAEs, anti-PD-L1 monotherapy lowers the risk of AEs in the 1L treatment of advanced NSCLC patients as compared to platinum-based chemotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.